The Greater Cannabis Company, Inc. (GCAN)
- Previous Close
0.0006 - Open
0.0006 - Bid --
- Ask --
- Day's Range
0.0006 - 0.0008 - 52 Week Range
0.0003 - 0.0015 - Volume
147,500 - Avg. Volume
3,545,385 - Market Cap (intraday)
643,710 - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.
www.gcanrx.com1
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GCAN
Performance Overview: GCAN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GCAN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GCAN
Valuation Measures
Market Cap
482.78k
Enterprise Value
756.47k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.44
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.42%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-188.4k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
166.86k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-32.52k
Company Insights: GCAN
GCAN does not have Company Insights